Natco Board Approves Proposal to Acquire U.S. Pharmaceutical Company

Natco Pharma announced on Tuesday that its board of directors had approved a proposed acquisition of US-based Dash Pharmaceuticals LLC for cash consideration of $18 million.

The company’s board of directors has approved the acquisition of Dash Pharmaceuticals through one of its subsidiaries, the drugmaker said in a regulatory filing.

Natco, through its affiliates, is offering to enter into an agreement to acquire Dash Pharmaceuticals subject to the satisfactory completion of due diligence, execution of definitive agreements and compliance with legal requirements, it said. he adds.

Dash is a pharmaceutical sales, marketing and distribution entity based in New Jersey, United States, which is expected to have net sales of approximately $15 million for the year ending December 2021.

This acquisition will provide the company with a front-end to engage directly with its customers in the United States, which is the world’s largest pharmaceutical market, Natco Pharma noted.

(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

Comments are closed.